Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aquestive Therapeutics Inc
(NQ:
AQST
)
2.310
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 31, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
2.310
Bid (Size)
2.310 (2)
Ask (Size)
2.680 (6)
Prev. Close
2.310
Today's Range
2.310 - 2.310
52wk Range
0.6180 - 2.690
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Aquestive Therapeutics Reports Positive Results from Latest Clinical Studies Evaluating Pharmacokinetic and Pharmacodynamic Performance of Anaphylm ™ (epinephrine) Sublingual Film and Provides Findings from Recent Auto-Injector Clinical Study
May 31, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
May 12, 2023
Via
Benzinga
Performance
YTD
+156.70%
+156.70%
1 Month
+66.19%
+66.19%
3 Month
+199.96%
+199.96%
6 Month
+148.92%
+148.92%
1 Year
+132.39%
+132.39%
More News
Read More
Aquestive Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 02, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Earnings Outlook For Aquestive Therapeutics
May 01, 2023
Via
Benzinga
Earnings Outlook For Aquestive Therapeutics
March 06, 2023
Via
Benzinga
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
April 26, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Receives Conditional FDA Acceptance of Proprietary Name Anaphylm™ for Lead Candidate AQST-109 (Epinephrine Sublingual Film)
April 20, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 2 and Host Conference Call on May 3 at 8:00 a.m. ET
April 18, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Expands License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film to Additional Global Markets
March 29, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives
March 07, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference
March 01, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Report Fourth Quarter 2022 Financial Results and Recent Business Highlights on March 7 and Host Conference Call on March 8 at 8:00 a.m. ET
February 22, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for AQST-109 Epinephrine Sublingual Film at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
February 21, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
February 15, 2023
Via
Benzinga
Aquestive Therapeutics Provides Business Update and Outlines Key 2023 Objectives
January 06, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109 (epinephrine sublingual film)
December 22, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Announces Publication of Crossover Food Effect Study of Diazepam Nasal Spray in Epilepsia
November 29, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
November 15, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic Studies for AQST-109 (epinephrine sublingual film) at American Academy of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting
November 09, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Looking Into Aquestive Therapeutics's Return On Capital Employed
November 09, 2022
Via
Benzinga
Aquestive Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 01, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Earnings Preview
October 31, 2022
Via
Benzinga
Aquestive Therapeutics Licenses Sympazan® (clobazam) Oral Film to Assertio Holdings, Inc.
October 27, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Announces Positive Decision in States’ Suboxone Antitrust Lawsuit on All Claims
October 24, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Report Third Quarter 2022 Financial Results and Recent Business Highlights on November 1 and Host Conference Call on November 2 at 8:00 a.m. ET
October 19, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.